Its a sad reality overlooked by so many investors in the micro/mini-capped end of early to mid-stage bio-techs. The slow decay effect on early investment returns by continued dilution for ongoing capital needs and cash burn.
I've held off investing IMU for years and only bought in with any volume recently and am nursing some vivid tyre tracks on my forehead, I will happily concede - nothing to longer term investors I appreciate. Perhaps lighten up on the focus of their mistakes therein JP. This investing malarky is done ultimately in the context of level II chaos systems that mkts are, and a tad hard to predict.
Lesley Wong needs very clear signalling at the next AGM with a wealth of Hot Copper 'no' votes on her remuneration at least, for the lack of partnership results in my opinion. There really should have been a solid partnership bearing upfront and milestone payments in Azer-cel by now if nothing else, if truly "Azer-cel is a potential First-in Class Allogeneic CAR T Product Candidate for CD19+ CAR T Relapsed Patients ".
This consolidation ultimately a reflection of failures therein.
IMU Price at posting:
1.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)